{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:42:28Z","timestamp":1790991748144,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,11]]},"DOI":"10.7759\/cureus.69208","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:05:45Z","timestamp":1726085145000},"source":"Crossref","is-referenced-by-count":8,"title":["Neurosarcoidosis: Current Perspectives on Diagnosis, Management, and Future Directions"],"prefix":"10.7759","author":[{"given":"Tanya","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaira","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Namal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Vineesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Warsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Faqeer Hussain","family":"Bokhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mudasser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Sarcoidosis","author":"Bokhari SRA","year":"2024","unstructured":"Bokhari SRA, Zulfiqar H, Mansur A. Sarcoidosis. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref2","article-title":"Geoepidemiological big data approach to sarcoidosis: Geographical and ethnic determinants","volume":"37","author":"Brito-Zer\u00f3n P","year":"2019","unstructured":"Brito-Zer\u00f3n P, Kostov B, Superville D, Baughman RP, Ramos-Casals M. Geoepidemiological big data approach to sarcoidosis: Geographical and ethnic determinants. Clin Exp Rheumatol. 2019, 37:1052-64.","journal-title":"Clin Exp Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: Recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema EV","year":"2020","unstructured":"Arkema EV, Cozier YC. Sarcoidosis epidemiology: Recent estimates of incidence, prevalence and risk factors. Curr Opin Pulm Med. 2020, 26:527-34. 10.1097\/MCP.0000000000000715","journal-title":"Curr Opin Pulm Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis: Pathophysiology, diagnosis, and treatment","volume":"8","author":"Bradshaw MJ","year":"2021","unstructured":"Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: Pathophysiology, diagnosis, and treatment. Neurol Neuroimmunol Neuroinflamm. 2021, 8:10.1212\/NXI.0000000000001084","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-023-01092-z","article-title":"Neurosarcoidosis: Diagnostic challenges and mimics a review","volume":"23","author":"Shen J","year":"2023","unstructured":"Shen J, Lackey E, Shah S. Neurosarcoidosis: Diagnostic challenges and mimics a review. Curr Allergy Asthma Rep. 2023, 23:399-410. 10.1007\/s11882-023-01092-z","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170175","article-title":"Neurosarcoidosis: A review of its intracranial manifestation","volume":"248","author":"Nowak DA","year":"2001","unstructured":"Nowak DA, Widenka DC. Neurosarcoidosis: A review of its intracranial manifestation. J Neurol. 2001, 248:363-72. 10.1007\/s004150170175","journal-title":"J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000684","article-title":"Management of neurosarcoidosis: A clinical challenge","volume":"32","author":"Voortman M","year":"2019","unstructured":"Voortman M, Drent M, Baughman RP. Management of neurosarcoidosis: A clinical challenge. Curr Opin Neurol. 2019, 32:475-83. 10.1097\/WCO.0000000000000684","journal-title":"Curr Opin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/157015911796557975","article-title":"Neurosarcoidosis","volume":"9","author":"Lacomis D","year":"2011","unstructured":"Lacomis D. Neurosarcoidosis. Curr Neuropharmacol. 2011, 9:429-36. 10.2174\/157015911796557975","journal-title":"Curr Neuropharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: Systematic review and meta-analysis","volume":"16","author":"Fritz D","year":"2016","unstructured":"Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: Systematic review and meta-analysis. BMC Neurol. 2016, 16:220. 10.1186\/s12883-016-0741-x","journal-title":"BMC Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-018-1842-5","article-title":"Sarcoid uveitis in a patient with multiple neurological lesions: A case report and review of the literature","volume":"12","author":"Ohno T","year":"2018","unstructured":"Ohno T, Ishihara M, Shibuya E, Mizuki N. Sarcoid uveitis in a patient with multiple neurological lesions: A case report and review of the literature. J Med Case Rep. 2018, 12:307. 10.1186\/s13256-018-1842-5","journal-title":"J Med Case Rep"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1097\/00005792-199009000-00001","article-title":"Neurosarcoidosis: Signs, course and treatment in 35 confirmed cases","volume":"69","author":"Chapelon C","year":"1990","unstructured":"Chapelon C, Ziza JM, Piette JC, et al.. Neurosarcoidosis: Signs, course and treatment in 35 confirmed cases. Medicine (Baltimore). 1990, 69:261-76.","journal-title":"Medicine (Baltimore)"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1997.00440370104011","article-title":"Diagnosis and management of neurological sarcoidosis","volume":"157","author":"Lower EE","year":"1997","unstructured":"Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997, 157:1864-8.","journal-title":"Arch Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200028","article-title":"Pachymeningitis in biopsy-proven sarcoidosis: Clinical course, radiographic findings, response to treatment, and long-term outcomes","volume":"9","author":"Chakales PA","year":"2022","unstructured":"Chakales PA, Herman MC, Chien LC, Hutto SK. Pachymeningitis in biopsy-proven sarcoidosis: Clinical course, radiographic findings, response to treatment, and long-term outcomes. Neurol Neuroimmunol Neuroinflamm. 2022, 9:10.1212\/NXI.0000000000200028","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31815585aa","article-title":"Sarcoidosis: Clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature","volume":"86","author":"Bihan H","year":"2007","unstructured":"Bihan H, Christozova V, Dumas JL, et al.. Sarcoidosis: Clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore). 2007, 86:259-68. 10.1097\/MD.0b013e31815585aa","journal-title":"Medicine (Baltimore)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_987_23","article-title":"Neurosarcoidosis: An under-diagnosed cause of myelopathy","volume":"13","author":"Chaubey M","year":"2024","unstructured":"Chaubey M, Meena K, Singh T, et al.. Neurosarcoidosis: An under-diagnosed cause of myelopathy. J Family Med Prim Care. 2024, 13:2157-60. 10.4103\/jfmpc.jfmpc_987_23","journal-title":"J Family Med Prim Care"},{"key":"ref16","article-title":"Neurosarcoidosis","author":"Pirau L","year":"2024","unstructured":"Pirau L, Lui F. Neurosarcoidosis. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11481","article-title":"Hypothalamic-pituitary axis dysfunction, central diabetes insipidus, and syndrome of inappropriate antidiuretic hormone secretion as the first clinical presentation of neurosarcoidosis: Why early diagnosis and treatment is important?","volume":"12","author":"Blazin T","year":"2020","unstructured":"Blazin T, Prajapati D, Mohammed LL, et al.. Hypothalamic-pituitary axis dysfunction, central diabetes insipidus, and syndrome of inappropriate antidiuretic hormone secretion as the first clinical presentation of neurosarcoidosis: Why early diagnosis and treatment is important?. Cureus. 2020, 12:e11481. 10.7759\/cureus.11481","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345093","article-title":"Endocrine aspects of neurosarcoidosis","volume":"25","author":"Murialdo G","year":"2002","unstructured":"Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis. J Endocrinol Invest. 2002, 25:650-62. 10.1007\/BF03345093","journal-title":"J Endocrinol Invest"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-57642013DN74000012","article-title":"Rapidly progressive dementia due to neurosarcoidosis","volume":"7","author":"Fortes GC","year":"2013","unstructured":"Fortes GC, Oliveira MC, Lopes LC, Tomikawa CS, Lucato LT, Castro LH, Nitrini R. Rapidly progressive dementia due to neurosarcoidosis. Dement Neuropsychol. 2013, 7:428-34. 10.1590\/S1980-57642013DN74000012","journal-title":"Dement Neuropsychol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.17712\/nsj.2020.5.20200090","article-title":"Isolated neurosarcoidosis mimicking multiple sclerosis","volume":"25","author":"Al Malik YM","year":"2020","unstructured":"Al Malik YM. Isolated neurosarcoidosis mimicking multiple sclerosis. Neurosciences (Riyadh). 2020, 25:406-11. 10.17712\/nsj.2020.5.20200090","journal-title":"Neurosciences (Riyadh)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.594275","article-title":"Sarcoidosis: Pitfalls and challenging mimickers","volume":"7","author":"Narula N","year":"2021","unstructured":"Narula N, Iannuzzi M. Sarcoidosis: Pitfalls and challenging mimickers. Front Med (Lausanne). 2021, 7:594275. 10.3389\/fmed.2020.594275","journal-title":"Front Med (Lausanne)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2014Diagnosis and management","volume":"92","author":"Zajicek JP","year":"1999","unstructured":"Zajicek JP, Scolding NJ, Foster O, et al.. Central nervous system sarcoidosis\u2014Diagnosis and management. QJM. 1999, 92:103-17. 10.1093\/qjmed\/92.2.103","journal-title":"QJM"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0043-5","article-title":"Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy","volume":"253","author":"Marangoni S","year":"2006","unstructured":"Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol. 2006, 253:488-95. 10.1007\/s00415-005-0043-5","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000477300","article-title":"Characteristics and long-term outcome of neurosarcoidosis: A population-based study from 1976-2013","volume":"48","author":"Ungprasert P","year":"2017","unstructured":"Ungprasert P, Crowson CS, Matteson EL. Characteristics and long-term outcome of neurosarcoidosis: A population-based study from 1976-2013. Neuroepidemiology. 2017, 48:87-94. 10.1159\/000477300","journal-title":"Neuroepidemiology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2011.12.017","article-title":"Neurosarcoidosis: Clinical manifestations, diagnosis and treatment","volume":"41","author":"Nozaki K","year":"2012","unstructured":"Nozaki K, Judson MA. Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Med. 2012, 41:e331-48. 10.1016\/j.lpm.2011.12.017","journal-title":"Presse Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group","volume":"75","author":"Stern BJ","year":"2018","unstructured":"Stern BJ, Royal W 3rd, Gelfand JM, et al.. Definition and consensus diagnostic criteria for neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018, 75:1546-53. 10.1001\/jamaneurol.2018.2295","journal-title":"JAMA Neurol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.182.2.1820289","article-title":"Imaging manifestations of neurosarcoidosis","volume":"182","author":"Smith JK","year":"2004","unstructured":"Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004, 182:289-95. 10.2214\/ajr.182.2.1820289","journal-title":"AJR Am J Roentgenol"},{"key":"ref28","article-title":"Neurosarcoidosis presenting as acute infarction on diffusion-weighted MR imaging: Summary of radiologic findings","volume":"28","author":"Hodge MH","year":"2007","unstructured":"Hodge MH, Williams RL, Fukui MB. Neurosarcoidosis presenting as acute infarction on diffusion-weighted MR imaging: Summary of radiologic findings. AJNR Am J Neuroradiol. 2007, 28:84-6.","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/1971400918806634","article-title":"Imaging findings in spinal sarcoidosis: A report of 18 cases and review of the current literature","volume":"32","author":"Soni N","year":"2019","unstructured":"Soni N, Bathla G, Pillenahalli Maheshwarappa R. Imaging findings in spinal sarcoidosis: A report of 18 cases and review of the current literature. Neuroradiol J. 2019, 32:17-28. 10.1177\/1971400918806634","journal-title":"Neuroradiol J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2021.05.001","article-title":"Susceptibility-weighted imaging in neuroradiology: Practical imaging principles, pearls and pitfalls","volume":"51","author":"Aker L","year":"2022","unstructured":"Aker L, Abandeh L, Abdelhady M, Aboughalia H, Vattoth S. Susceptibility-weighted imaging in neuroradiology: Practical imaging principles, pearls and pitfalls. Curr Probl Diagn Radiol. 2022, 51:568-78. 10.1067\/j.cpradiol.2021.05.001","journal-title":"Curr Probl Diagn Radiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-611","article-title":"Value of 18-fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG PET\/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: A retrospective study","volume":"11","author":"Chen X","year":"2022","unstructured":"Chen X, Xu X, Chrysikos S, Zhao M, Zhou Y. Value of 18-fluorodeoxyglucose positron emission tomography\/computed tomography (18F-FDG PET\/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: A retrospective study. Transl Lung Cancer Res. 2022, 11:1926-35. 10.21037\/tlcr-22-611","journal-title":"Transl Lung Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000892","article-title":"The role of PET in the management of sarcoidosis","volume":"28","author":"Vender RJ","year":"2022","unstructured":"Vender RJ, Aldahham H, Gupta R. The role of PET in the management of sarcoidosis. Curr Opin Pulm Med. 2022, 28:485-91. 10.1097\/MCP.0000000000000892","journal-title":"Curr Opin Pulm Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33631-z","article-title":"A comprehensive diagnostic approach in suspected neurosarcoidosis","volume":"13","author":"Berntsson SG","year":"2023","unstructured":"Berntsson SG, Elmgren A, Gudjonsson O, Grabowska A, Landtblom AM, Moraes-Fontes MF. A comprehensive diagnostic approach in suspected neurosarcoidosis. Sci Rep. 2023, 13:6539. 10.1038\/s41598-023-33631-z","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.05.020","article-title":"Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis","volume":"285","author":"Bridel C","year":"2015","unstructured":"Bridel C, Courvoisier DS, Vuilleumier N, Lalive PH. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis. J Neuroimmunol. 2015, 285:1-3. 10.1016\/j.jneuroim.2015.05.020","journal-title":"J Neuroimmunol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1135392","article-title":"Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction","volume":"14","author":"Vlad B","year":"2023","unstructured":"Vlad B, Neidhart S, Hilty M, Ziegler M, Jelcic I. Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction. Front Neurol. 2023, 14:1135392. 10.3389\/fneur.2023.1135392","journal-title":"Front Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000725","article-title":"Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis","volume":"7","author":"Otto C","year":"2020","unstructured":"Otto C, Wengert O, Unterwalder N, Meisel C, Ruprecht K. Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020, 7:10.1212\/NXI.0000000000000725","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205790","article-title":"Defining the CSF cytokine and chemokine signature of neurosarcoidosis (s38.009)","volume":"102","author":"Mangioris G","year":"2024","unstructured":"Mangioris G, Pittock S, Yang B, et al.. Defining the CSF cytokine and chemokine signature of neurosarcoidosis (s38.009). Neurology. 2024, 102:10.1212\/WNL.0000000000205790","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis","volume":"14","author":"Eurelings LE","year":"2019","unstructured":"Eurelings LE, Miedema JR, Dalm VA, van Daele PL, van Hagen PM, van Laar JA, Dik WA. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019, 14:e0223897. 10.1371\/journal.pone.0223897","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1263-z","article-title":"Chitotriosidase: A biomarker of activity and severity in patients with sarcoidosis","volume":"21","author":"Bennett D","year":"2020","unstructured":"Bennett D, Cameli P, Lanzarone N, et al.. Chitotriosidase: A biomarker of activity and severity in patients with sarcoidosis. Respir Res. 2020, 21:6. 10.1186\/s12931-019-1263-z","journal-title":"Respir Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2019.04.006","article-title":"Clinical manifestations, diagnosis, and treatment of sarcoidosis","volume":"3","author":"Ungprasert P","year":"2019","unstructured":"Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019, 3:358-75. 10.1016\/j.mayocpiqo.2019.04.006","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"ref41","article-title":"Corticosteroid adverse effects","author":"Yasir M","year":"2024","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. StatPearls (ed): StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051250","article-title":"Clinical pharmacology in sarcoidosis: How to use and monitor sarcoidosis medications","volume":"13","author":"Kwon S","year":"2024","unstructured":"Kwon S, Judson MA. Clinical pharmacology in sarcoidosis: How to use and monitor sarcoidosis medications. J Clin Med. 2024, 13:1250. 10.3390\/jcm13051250","journal-title":"J Clin Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51968","article-title":"Infliximab in neurosarcoidosis: A systematic review and meta-analysis","volume":"11","author":"Chaiyanarm S","year":"2024","unstructured":"Chaiyanarm S, Satiraphan P, Apiraksattaykul N, Jitprapaikulsan J, Owattanapanich W, Rungjirajittranon T, Nanthasi W. Infliximab in neurosarcoidosis: A systematic review and meta-analysis. Ann Clin Transl Neurol. 2024, 11:466-76. 10.1002\/acn3.51968","journal-title":"Ann Clin Transl Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz D","year":"2020","unstructured":"Fritz D, Timmermans WM, van Laar JA, van Hagen PM, Siepman TA, van de Beek D, Brouwer MC. Infliximab treatment in pathology-confirmed neurosarcoidosis. Neurol Neuroimmunol Neuroinflamm. 2020, 7:10.1212\/NXI.0000000000000847","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series","volume":"89","author":"Gelfand JM","year":"2017","unstructured":"Gelfand JM, Bradshaw MJ, Stern BJ, et al.. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017, 89:2092-100. 10.1212\/WNL.0000000000004644","journal-title":"Neurology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart F","year":"2017","unstructured":"Cohen Aubart F, Bouvry D, Galanaud D, et al.. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017, 264:891-7. 10.1007\/s00415-017-8444-9","journal-title":"J Neurol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325665","article-title":"TNF-\u03b1 inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis","volume":"92","author":"Hilezian F","year":"2021","unstructured":"Hilezian F, Maarouf A, Boutiere C, et al.. TNF-\u03b1 inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis. J Neurol Neurosurg Psychiatry. 2021, 92:890-6. 10.1136\/jnnp-2020-325665","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref48","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss NJ","year":"2014","unstructured":"Sweiss NJ, Noth I, Mirsaeidi M, et al.. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014, 31:46-54.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418805732","article-title":"Successful therapy with rituximab in three patients with probable neurosarcoidosis","volume":"11","author":"Zella S","year":"2018","unstructured":"Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Th\u00f6ne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018, 11:10.1177\/1756286418805732","journal-title":"Ther Adv Neurol Disord"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0025-9","article-title":"Rituximab in refractory sarcoidosis: A single centre experience","volume":"13","author":"Cinetto F","year":"2015","unstructured":"Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: A single centre experience. Clin Mol Allergy. 2015, 13:19. 10.1186\/s12948-015-0025-9","journal-title":"Clin Mol Allergy"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7ff9","article-title":"A case of neurosarcoidosis successfully treated with rituximab","volume":"75","author":"Bomprezzi R","year":"2010","unstructured":"Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010, 75:568-70. 10.1212\/WNL.0b013e3181ec7ff9","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/286230-neurosarcoidosis-current-perspectives-on-diagnosis-management-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:05:50Z","timestamp":1726085150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/286230-neurosarcoidosis-current-perspectives-on-diagnosis-management-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.69208","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}